CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
US12006367B2 · kind B2 · utility
0Cited by
7References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2022 |
| Grant date | Jun 11, 2024 |
| Priority date | — |
| Expiry date | Jun 9, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to hetero-dimeric immunoglobulins that target both a component of the human CD3 antigen and a component of the human CD38 antigen and methods of making the same. The present invention also relates to antibodies which bind to the human CD38 antigen and derivatives thereof for use as therapeutic or diagnostic reagents and methods of making the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.